Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abvc Biopharma (ABVC) Interest Expenses (2016 - 2025)

Abvc Biopharma (ABVC) has disclosed Interest Expenses for 13 consecutive years, with $32551.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Interest Expenses fell 84.98% year-over-year to $32551.0, compared with a TTM value of $415890.0 through Dec 2025, down 49.64%, and an annual FY2025 reading of $415890.0, down 49.64% over the prior year.
  • Interest Expenses was $32551.0 for Q4 2025 at Abvc Biopharma, up from $30959.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $1.2 million in Q3 2023 and bottomed at -$228798.0 in Q4 2021.
  • Average Interest Expenses over 5 years is $138111.6, with a median of $120644.0 recorded in 2022.
  • The sharpest move saw Interest Expenses plummeted 296.09% in 2021, then skyrocketed 2128.14% in 2022.
  • Year by year, Interest Expenses stood at -$228798.0 in 2021, then surged by 158.77% to $134461.0 in 2022, then plummeted by 156.8% to -$76368.0 in 2023, then skyrocketed by 383.78% to $216715.0 in 2024, then plummeted by 84.98% to $32551.0 in 2025.
  • Business Quant data shows Interest Expenses for ABVC at $32551.0 in Q4 2025, $30959.0 in Q3 2025, and $129413.0 in Q2 2025.